I-SENS, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 11, 2023 at 04:20 am EDT
Share
i-SENS, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 62,489.71 million compared to KRW 61,764.23 million a year ago. Net income was KRW 2,761.73 million compared to KRW 2,417.24 million a year ago. Basic earnings per share from continuing operations was KRW 100 compared to KRW 88 a year ago. Diluted earnings per share from continuing operations was KRW 100 compared to KRW 88 a year ago. Basic earnings per share was KRW 100 compared to KRW 88 a year ago.
For the six months, sales was KRW 580.76 million compared to KRW 1,996.29 million a year ago. Net income was KRW 6,975.83 million compared to KRW 15,417.77 million a year ago. Basic earnings per share from continuing operations was KRW 254 compared to KRW 561 a year ago. Diluted earnings per share from continuing operations was KRW 252 compared to KRW 561 a year ago. Basic earnings per share was KRW 254 compared to KRW 561 a year ago. Diluted earnings per share was KRW 252.
i-SENS, Inc. is a Korea-based company mainly engaged in the manufacture and sale of biosensors. The Companyâs products consist of blood glucose monitoring systems, including blood glucose monitors, blood glucose meters, glucose monitors, blood glucose meter kits and blood sugar meters under the brand names of CareSens, MedTrust, BGStar, Barozen and others; electrolyte analyzers and cartridges; immunosensors, as well as other related accessories, such as connectors, lancets, blood glucose data management software and lancing devices, among others. The Company distributes its products within domestic market and to overseas markets including Japan, Europe, the United States and others.
I-SENS, INC. 
